AbbVie Inc.

BIT:1ABBV Stock Report

Market Cap: €346.0b

AbbVie Valuation

Is 1ABBV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1ABBV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Fair Value: 1ABBV (€186.8) is trading below our estimate of fair value (€319.47)

Significantly Below Fair Value: 1ABBV is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1ABBV?

Key metric: As 1ABBV is barely profitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 1ABBV. This is calculated by dividing 1ABBV's market cap by their current revenue.
What is 1ABBV's PS Ratio?
PS Ratio6.8x
SalesUS$59.64b
Market CapUS$405.28b

Price to Sales Ratio vs Peers

How does 1ABBV's PS Ratio compare to its peers?

The above table shows the PS ratio for 1ABBV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average7.6x
PHIL Philogen
10.9x-45.40%€926.1m
GILD Gilead Sciences
5x3.87%US$146.8b
AMGN Amgen
4.8x2.40%US$172.7b
VRTX Vertex Pharmaceuticals
9.7x9.03%US$113.9b
1ABBV AbbVie
6.8x6.49%€405.3b

Price-To-Sales vs Peers: 1ABBV is good value based on its Price-To-Sales Ratio (6.8x) compared to the peer average (7.7x).

Historical Price to Sales Ratio

Historical Price to Sales Ratio compares a stock's price to its sales over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Sales Ratio vs Industry

How does 1ABBV's PS Ratio compare vs other companies in the European Biotechs Industry?

53 CompaniesPrice / SalesEstimated GrowthMarket Cap
1ABBV 6.8xIndustry Avg. 7.5xNo. of Companies53PS01224364860+
53 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 1ABBV is good value based on its Price-To-Sales Ratio (6.8x) compared to the European Biotechs industry average (7.4x).

Price to Sales Ratio vs Fair Ratio

What is 1ABBV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1ABBV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio6.8x
Fair PS Ratio20.6x

Price-To-Sales vs Fair Ratio: 1ABBV is good value based on its Price-To-Sales Ratio (6.8x) compared to the estimated Fair Price-To-Sales Ratio (20.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1ABBV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€186.80
€208.91
+11.84%
10.41%€246.75€157.10n/a28
Dec ’26€194.20
€210.09
+8.18%
10.27%€249.29€158.72n/a29
Nov ’26€189.60
€205.92
+8.61%
11.20%€246.37€159.62n/a27
Oct ’26€204.50
€194.11
-5.08%
9.07%€230.09€156.80n/a27
Sep ’26€179.20
€185.07
+3.28%
9.96%€218.00€145.33n/a27
Aug ’26€168.40
€184.05
+9.29%
10.29%€220.22€146.81n/a26
Jul ’26€161.40
€177.55
+10.00%
10.03%€212.25€144.33n/a27
Jun ’26€163.20
€184.62
+13.13%
9.87%€220.20€149.74n/a27
May ’26€169.40
€186.60
+10.15%
9.21%€221.43€153.23n/a27
Apr ’26€194.48
€196.25
+0.91%
9.14%€231.73€160.35n/a25
Mar ’26€197.52
€198.38
+0.44%
8.87%€230.44€159.09n/a26
Feb ’26€181.40
€196.16
+8.14%
8.70%€230.56€159.18n/a27
Jan ’26€169.26
€193.12
+14.10%
8.90%€228.84€157.33€195.2028
Dec ’25€173.06
€193.23
+11.65%
8.15%€226.80€155.93€194.2028
Nov ’25€187.66
€191.05
+1.81%
7.84%€220.66€156.30€189.6028
Oct ’25€178.54
€176.06
-1.39%
6.99%€195.28€152.29€204.5026
Sep ’25€175.82
€176.61
+0.45%
6.90%€196.13€152.95€179.2027
Aug ’25€176.28
€179.37
+1.75%
7.03%€198.55€157.00€168.4027
Jul ’25€159.56
€171.05
+7.20%
5.67%€192.78€156.46€161.4027
Jun ’25€145.18
€168.12
+15.80%
6.12%€190.58€148.23€163.2027
May ’25€151.56
€170.78
+12.68%
5.81%€192.14€150.16€169.4027
Apr ’25€167.90
€169.78
+1.12%
6.28%€190.20€148.65€194.4827
Mar ’25€163.60
€166.57
+1.82%
7.20%€189.85€141.00€197.5226
Feb ’25€152.90
€159.19
+4.12%
9.42%€189.28€124.65€181.4027
Jan ’25€139.90
€153.42
+9.66%
10.62%€183.79€115.21€169.2628
€199.32
Fair Value
6.3% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/05 13:05
End of Day Share Price 2026/01/05 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AbbVie Inc. is covered by 53 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Luisa HectorBerenberg
Timothy AndersonBernstein